Human RBC alloimmunization evaluation after exposure to foreign E antigen of the rhesus system in transfusion
  
View Full Text  View/Add Comment  Download reader
DOI:10.46701/APJBG.20170116009
KeyWord:RBC alloimmunization, anti-E alloantibody, RBC transfusion
                 
AuthorInstitution
Pu Xu Department of Blood Transfusion, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, China.
Yan Li Department of Clinical Laboratory, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, China.
Su Zhou Department of Blood Transfusion, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, China.
Ziqi He Department of Blood Transfusion, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, China.
You Yang Department of Blood Transfusion, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, China.
Hua Yu Department of Blood Transfusion, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, China.
Hits: 2905
Download times: 2453
Abstract:
      Anti-E alloantibody has been one of the most frequently detected clinically significant alloantibodies in previous studies. Red blood cell (RBC) transfusion is unique in its common intravenous introduction of foreign E antigen and provides a valuable opportunity to study the human immunologic response to intravenous foreign E antigen. Patients exposed to foreign E antigen while receiving RBC transfusions are at risk of forming anti-E alloantibody. Valid estimates of anti-E alloimmunization risk are clinically important, but the forming mechanism of anti-E alloimmunization remains unclear. Here, we screened 516 inpatients at risk of exposure to foreign E antigen while receiving RBC transfusions and monitored the development of anti-E alloantibody for up to two years after left hospital. However, only 2 cases of anti-E alloimmunization were identified in this study. Patients who received RBC transfusion had a very high risk of exposure to foreign E antigen, but the anti-E alloantibody production incidence was very low and few anti-E alloantibodies were produced within 3 to 6 months after RBC transfusion in this study. Further research would contribute to our knowledge of the anti-E alloimmunization mechanism and prevent anti-E development, which would be significantly useful in clinical for transfusions, obstetric management, and the evaluation and management of transfusion reactions in laboratory and institutional resources and cost reduction in healthcare system.
Close